Literature DB >> 26450707

Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.

Dimitrios Papakostas1, Eggert Stockfleth2.   

Abstract

Imiquimod, a TLR7 agonist, is a novel immune response modifier currently widely used in the treatment of actinic keratoses (in situ squamous cell carcinoma). Imiquimod has revolutionized the treatment of field cancerization and has been approved for the treatment of superficial basal cell carcinoma with the recommendation of a 6-week treatment strategy, offering an alternative to surgery or other destructive treatment strategies.

Entities:  

Keywords:  5-FU; BCC nevus syndrome; Hedgehog signaling cascade; Mohs surgery; Toll-like receptor; actinic keratosis; basal cell carcinoma; condylomata accuminata; cytokines; field cancerization; imiquimod; immunosuppression; inflammation; interferon; nonmelanoma skin cancer; organ transplantation; photodynamic therapy; radiation; skin aging; sun exposure

Mesh：

Substances：

Year:  2015        PMID： 26450707     DOI： 10.2217/fon.15.192

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  6 in total

1.  Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments.

Authors:  Cristina Pellegrini; Augusto Orlandi; Gaetana Costanza; Alessandro Di Stefani; Antonella Piccioni; Antonella Di Cesare; Andrea Chiricozzi; Amedeo Ferlosio; Ketty Peris; Maria Concetta Fargnoli
Journal:  PLoS One       Date:  2017-08-22       Impact factor: 3.240

2.  EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica.

Authors:  Rana El Hajj; Hanady Bou Youness; Laurence Lachaud; Patrick Bastien; Carine Masquefa; Pierre-Antoine Bonnet; Hiba El Hajj; Ibrahim Khalifeh
Journal:  PLoS Negl Trop Dis       Date:  2018-11-21

Review 3.  Hedgehog/GLI signaling in tumor immunity - new therapeutic opportunities and clinical implications.

Authors:  Sandra Grund-Gröschke; Georg Stockmaier; Fritz Aberger
Journal:  Cell Commun Signal       Date:  2019-12-26       Impact factor: 5.712

4.  Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.

Authors:  Athina Angelopoulou; Nikos Alexandris; Evangelia Konstantinou; Konstantinos Mesiakaris; Charilaos Zanidis; Konstantinos Farsalinos; Konstantinos Poulas
Journal:  Environ Res       Date:  2020-06-23       Impact factor: 6.498

Review 5.  Photodynamic Therapy for Basal Cell Carcinoma: The Clinical Context for Future Research Priorities.

Authors:  Nicholas J Collier; Lesley E Rhodes
Journal:  Molecules       Date:  2020-11-18       Impact factor: 4.411

Review 6.  Soluble Factors and Receptors Involved in Skin Innate Immunity-What Do We Know So Far?

Authors:  Lucian G Scurtu; Olga Simionescu
Journal:  Biomedicines       Date:  2021-11-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.